Trials / Conditions / Stage II Bladder Cancer AJCC v8

Stage II Bladder Cancer AJCC v8

15 registered clinical trials studyying Stage II Bladder Cancer AJCC v8 — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment NCT07332351	University of Washington	Phase 2
Recruiting	Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks M NCT07061964	National Cancer Institute (NCI)	Phase 2
Recruiting	Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual NCT07097142	NRG Oncology	Phase 3
Recruiting	Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer NCT06470282	University of California, San Francisco	Phase 1 / Phase 2
Recruiting	Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Ca NCT06263153	Yuanquan Yang	Phase 2
Withdrawn	Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer N NCT05564416	National Cancer Institute (NCI)	Phase 2
Recruiting	Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Ca NCT05581589	University of Washington	Phase 2
Terminated	Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemothera NCT04871529	SWOG Cancer Research Network	Phase 2
Completed	Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer NCT04383743	University of Washington	Phase 2
Completed	Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes NCT04501913	City of Hope Medical Center	—
Active Not Recruiting	Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Can NCT03775265	National Cancer Institute (NCI)	Phase 3
Active Not Recruiting	Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study NCT06350734	Mayo Clinic	—
Completed	Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Partici NCT03617913	Mayo Clinic	Phase 2
Completed	Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy NCT03319745	M.D. Anderson Cancer Center	Phase 2
Completed	Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer NCT00749892	M.D. Anderson Cancer Center	Phase 2